(Q36786512)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17420764%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

review article

1 reference

title

Immunology and immunotherapy approaches for prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17420764%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17420764%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Elkord E

series ordinal

1

1 reference

16 August 2017

publication date

10 April 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17420764%20AND%20SRC:MED&resulttype=core&format=json

Prostate Cancer and Prostatic Diseases

28 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17420764%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17420764%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17420764%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

224-236

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17420764%20AND%20SRC:MED&resulttype=core&format=json

Innovations and strategies for the development of anticancer vaccines

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Cancer immunotherapy: a treatment for the masses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Shedding light on immunotherapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Direct activation of CD8+ cytotoxic T lymphocytes by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Immunobiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

The use of dendritic cells in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

T-cell regulation by CD28 and CTLA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Functional T cells in athymic nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

The three Es of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Suppression of lymphoma and epithelial malignancies effected by interferon gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

A new era for cancer immunotherapy based on the genes that encode cancer antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Serological analysis of human tumor antigens: molecular definition and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

A listing of human tumor antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Progress in human tumour immunology and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Immune surveillance against a solid tumor fails because of immunological ignorance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Molecular characterization of defective antigen processing in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Costimulation of T cells for tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Increased interleukin-10 serum levels in patients with solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Role of TGF-beta in immune-evasion of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Phenotypic analysis of antigen-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Antibody-dependent cell-mediated cytotoxicity: a flow cytometry-based assay using fluorophores

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

21 January 2018

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

21 January 2018

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Dietary fat and prostate cancer: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Precipitating antigens of the normal human prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Characterization of the human kallikrein locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

The expanded human kallikrein gene family: locus characterization and molecular cloning of a new member, KLK-L3 (KLK9).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

cDNA coding for the entire human prostate specific antigen shows high homologies to the human tissue kallikrein genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Prostate-specific Antigen and Human Glandular Kallikrein: Two Kallikreins of the Human Prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Molecular cloning of human prostate specific antigen cDNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Prostate-specific antigen in serum of women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Prognostic and predictive factors in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

The dynamics of prostate-specific antigen in benign and malignant diseases of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Homeostasis and self-tolerance in the immune system: turning lymphocytes off.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Development of dendritic-cell based prostate cancer vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Tumor immunotherapy: inching toward the finish line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Follow-up evaluation of a phase II prostate cancer vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

DNA vaccines: an active immunization strategy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Cellular protein is the source of cross-priming antigen in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Reverse ELISPOT assay for clonal analysis of cytokine production I. Enumeration of gamma-interferon-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Molecular genetics of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Original Articles: Prostate Cancer: Measurement of Serum Prostate Specific Antigen Levels in Women and in Prostatectomized Men With an Ultrasensitive Immunoassay Technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

Immunodeficiency states and related malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

1 reference

7 January 2021

Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

A new era of cancer immunotherapy: converting theory to performance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Purification of cytomegalovirus-specific CD8 T cells from peripheral blood using HLA-peptide tetramers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Flow cytometric analysis of natural killer cell function as a clinical assay

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Guidelines on the management of prostate cancer.A document for local expert groups in the United Kingdompreparing prostate management policy documents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Isolation, characterization and amino-acid sequence of gamma-seminoprotein, a glycoprotein from human seminal plasma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Prostate antigen: A new potential marker for prostatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Advances in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Carcinoma of the prostate: results of post-irradiation biopsy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Prostate biopsy after definitive treatment by interstitial 125iodine implant or external beam radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021

Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500964

7 January 2021